HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation-Reference-Cited by-同舟云学术

HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation

Published:2019-03-05 Issue:7751 Volume:568 Page:244-248
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Gupta Ravindra K.,Abdul-Jawad Sultan,McCoy Laura E.,Mok Hoi Ping,Peppa Dimitra,Salgado Maria,Martinez-Picado Javier,Nijhuis Monique,Wensing Annemarie M. J.,Lee Helen,Grant Paul,Nastouli Eleni,Lambert Jonathan,Pace Matthew,Salasc Fanny,Monit Christopher,Innes Andrew J.,Muir Luke,Waters Laura,Frater John,Lever Andrew M. L.,Edwards Simon G.,Gabriel Ian H.,Olavarria Eduardo

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41586-019-1027-4.pdf

Reference31 articles.

1. Hütter, G. et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 360, 692–698 (2009).

2. Allers, K. et al. Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. Blood 117, 2791–2799 (2011).

3. UNAIDS. UNAIDS Data 2017 http://www.unaids.org/en/resources/documents/2017/20170720_Data_book_2017 (2017).

4. Gupta, R. K. et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infect. Dis. 18, 346–355 (2018).

5. The TenoRes Study Group. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. Lancet Infect. Dis. 16, 565–575 (2016).

Cited by 466 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biological Barriers for Drug Delivery and Development of Innovative Therapeutic Approaches in HIV, Pancreatic Cancer, and Hemophilia A/B;Pharmaceutics;2024-09-13

2. Low prevalence of HIV in the northern Cameroon: contribution of some AIDS restriction genes and potential implications for gene therapy;Frontiers in Genetics;2024-09-13

3. HIV-Associated Immune Dysfunction and Hematological Abnormalities: A Detailed Examination of Pathophysiology and Clinical Implications;International Journal of Innovative Science and Research Technology (IJISRT);2024-09-12

4. Anti-PD-L1 antibody ASC22 in combination with a histone deacetylase inhibitor chidamide as a “shock and kill” strategy for ART-free virological control: a phase II single-arm study;Signal Transduction and Targeted Therapy;2024-09-09

5. Cancer in People with HIV;Infectious Disease Clinics of North America;2024-09